Covid antibodies test results

The number 14 that I got from the blood test on Thursday for Covid antibodies is dismal if good immunity is 250. So I still have to be careful, definitely! Here is a message from the clinic:

RE: Covid antibodies

Please see the response from Megan, our physician assistant (at Seattle Cancer Care Alliance)

 

"So it looks like she did have a response to the vaccine, as evidenced by the 14 number at the top and the positive spike antibody. We don't exactly know though what this means, though, in terms of how protective this is. I would say that number is on the lower end but again that doesn't really mean anything (right now). The negative result at the bottom is the test for active covid infection and she didn't have that at the time of this test. I am happy to talk with her this week if she wants to discuss these results further. All of this said, positive antibodies does not mean "green light: GO". Especially with the new variants, it is important that she is still vigilant, follows CDC and DoH guidelines including, frequent hand washing and wears a mask when inside and in crowded places and avoiding unvaccinated or those who are showing signs/ symptoms concerning for COVID."

From the Leukemia & Lymphoma Society's study:

• Treatment with anti-CD20 antibodies, such as rituximab and obinutuzumab in the 6 to 12 months prior to COVID-19 vaccination blunts antibody response. Many of these patients have no detectable COVID-19 antibodies, even after a third dose of an mRNA vaccine (Moderna or Pfizer BioNTech).

The new study, drawing from a nationwide dataset gathered by the National COVID Cohort Collaborative, covered a sample of COVID-19 patients that was over 100 times larger than the preliminary study. The study found that overall, hospitalized COVID-19 patients taking immunosuppressive drugs did not face significant increases in the risk of COVID-19 death compared with non-immunosuppressed hospitalized COVID-19 patients.

Of the 303 drugs examined in the study, the authors found that one drug, rituximab, a monoclonal antibody preparation that targets antibody-producing B cells, was associated with a substantially increased risk of death compared to medically similar hospitalized COVID-19 patients. Rituximab is used for serious medical conditions like cancer or an autoimmune disorder that has not responded to other treatments.

https://publichealth.jhu.edu/2021/outcomes-for-hospitalized-covid-19-patients-taking-immunosuppressive-medications-similar-to-non-immunosuppressed-patients?fbclid=IwAR1DCkZCQP7h2_EEBy3QLvF1h2rWglC5WGZd2aT0NA0K91atjLNwE_W5yyY